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ABSTRACT 
The effects of bisoprolol 10 mg once daily, isosorbide dinitrate (ISDN) 
20 mg three times daily, or a combination of these drugs on ischemia 
during exercise testing and on the occurrence and the circadian vari- 
ation of ischemia during ambulatory monitoringwere evaluated in23 
patients with stable angina pectoris. ISDN and bisoprolol monother- 
apies both significantly reduced the number of patients with angina 
pectoris and ST-depression during ergometry while lengthening the 
time to occurrence of 0.1-mV ST-depression. ISDN did not reduce the 
number of ischemic episodes measured by Holter monitoring, al- 
though it did significantly reduce the duration of ischemia. Bisoprolol 
monotherapy and combination therapy significantly reduced the num- 
ber of ischemic episodes as well as the duration of ischemia, total 
ischemic burden, and number of anginal attacks. The circadian vari- 
ation of ischemia s measured by Holter monitor was completely abol- 
ished by bisoprolol monotherapy and by combination therapy. ISDN 
monotherapy reduced the evening peak of ischemia but only shortened 
the morning peak. Both bisopro[ol and ISDN reduced ischemia during 
formal exercise testing, but only bisoprolol effectively reduced the 
total amount of daily life ischemia s measured by ambulatory 
monitoring. 
INTRODUCTION 
The problem of silent ischemia, defined as objective vidence for transient 
myocardial ischemia in the absence of symptoms, might be associated with 
adverse outcome, 1-3 although other evidence contradicts his. 4-s Whether 
medical treatment of silent ischemia can influence prognosis is still under 
investigation. 
Many episodes of silent ischemia occur during low levels of physical 
activity and during low heart rates, suggesting that not only an increased 
oxygen demand, but also changes in blood supply, might play a role. Cyclic 
variations of coronary vascular tone, heart rate, and blood pressure give 
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rise to a clear circadian rhythm in the occurrence of ischemic episodes. The 
circadian distribution of transient myocardial ischemia usually shows a 
morning peak and a smaller secondary peak in the evening, while occur- 
rences of myocardial infarction, ventricular tachycardia, sudden death, 
and cerebral stroke only show a morning peak. 7-9 It is conceivable that the 
different ypes of anti-ischemic drugs influence the circadian rhythm in 
different ways, according to their mechanisms of action. Likewise, the 
duration of action and the dosage schedule of an antianginal drug might 
influence its effect on the circadian variation of ischemia. So far, only 
beta-adrenergic blockers have proven to abolish the morning peak in the 
circadian variation of transient ischemia, myocardial infarction, and sud- 
den death. Organic nitrates have proven their anti-ischemic efficacy, but 
few studies of the influence of nitrates on the circadian variation of isch- 
emia have been performedJ °'11 
In this randomized, ouble-blind, placebo-controlled, crossover study, 
we investigated the effects of isosorbide dinitrate (ISDN) and bisoprolol on 
the occurrence and circadian distribution of silent and symptomatic sch- 
emia during daily activities. ISDN is effective for approximately 2 to 8 
hours after administration, and a nitrate-free interval is needed to avoid 
toleranceJ 2-14 Bisoprolol is a highly betal-adrenergic-selective blocker 
with a long plasma-elimination half-life (10 to 12 hours), making it still 
effective 24 hours after administration. The combination of bisoprolol and 
ISDN was also studied to see whether this resulted in further beneficial 
effects. 
We compared the number and duration of ischemic episodes during a 
48-hour Holter registration, and the total exercise time, ST-depression, 
and anginal complaints during a bicycle exercise tolerance test (ETT) at 
the end of each treatment period. 
PAT IENTS AND METHODS 
Patients 
Patients aged 21 to 75 years with stable angina pectoris, angiograph- 
ically proven coronary artery disease (at least one stenosis of >/ 70%), at 
least 0.1-mV ST-depression during an ETT, and at least four ischemic 
episodes on a 48-hour Holter monitoring during the placebo phase were 
included. For women, coronary artery disease had to be proven by either a 
previous myocardial infarction, a positive exercise thallium scan, or a 
coronary angiogram. For men, coronary artery disease was proven by ex- 
ercise test with ~>0.1-mV ST-depression. 
Excluded from the study were women of childbearing age; patients 
with unstable angina, myocardial infarction <6 months prior to enroll- 
ment, severe angina, arrhythmias requiring medical treatment, severe 
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hypertension (diastolic >105 mm Hg), bradycardia (<45 beats/min), any 
degree of atrioventricular block, chronic obstructive pulmonary disease, 
hemodynamically important valvular disease, overt heart failure, and pa- 
tients unable to exercise or with an uninterpretable ST-segment on elec- 
trocardiogram (ECG). Use of vasodilators, beta-adrenergic blockers, long- 
acting nitrates, and digitalis was forbidden during the study. The hospital 
ethics committee approved the protocol, and each patient gave written 
informed consent before entering the study. 
Study Design 
The study consisted of a 2-week single-blind placebo prephase and 
three randomized, ouble-blind, crossover treatment periods of 4 weeks 
each. There were no washout phases between the different treatments, but 
the 4-week treatment length ensured that the measurements a  the end of 
each treatment could not be influenced by the previous treatment. 
Treatment consisted of bisoprolol 10 mg once daily, or ISDN 20 mg 
three times daily (TID), or the combination, in random order. A double- 
dummy technique nsured the double blindness of the treatments. 
Any current antianginal or vasodilator therapy was discontinued be- 
fore the placebo phase. Only short-acting nitrates were allowed, but not 
prophylactically and not during the 2 hours immediately before the exer- 
cise tests. Patients were instructed to take their bisoprolol between 7 and 
10 AM and the ISDN with every main meal. At each study visit investi- 
gators checked compliance. Patients kept a diary for recording complaints 
and adverse vents, and they were questioned verbally at each visit. 
On day 5, an ETT was performed 2 to 3 hours after medication i take. 
If at least 0.1 mV of horizontal or downsloping ST-depression occurred, a
48-hour Holter recording was obtained. A second ETT was performed on 
day 14; for inclusion in the study, patients had to have <15% variability in 
total exercise time. In addition, patients were required to have at least four 
episodes of silent ischemia on the 48-hour Holter recording. Patients ful- 
filling these criteria entered the active treatment phase of the study. Two 
days before the end of each treatment phase a 48-hour Holter registration 
was started. On the last day an ETT was performed 2 to 3 hours after 
medication i take. 
The study ended with a final physical examination and a routine 
laboratory analysis (ie, erythrocyte sedimentation rate, hemogoblin, he- 
matocrit, leukocyte count, sodium, potassium, urea, creatinine, lactic acid 
dehydrogenase, aspartate aminotransferase, alanine aminotransferase, 
and glucose) after the third active treatment period was completed. 
Ambulatory ECG Analysis 
The continuous 48-hour ambulatory ECG recordings were performed 
on 3-channel amplitude-modulated Marquette ®recorders (Marquette 
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Electronics, Inc., Milwaukee, Wisconsin). We used modified leads aVF, Vl, 
and Vs. The computer analysis of each tape was manually checked by an 
experienced technician. Each episode of at least 0.1 mV of horizontal or 
downsloping ST-depression compared with baseline, measured 60 msec 
after the J-point, lasting for at least 1 minute, and separated from another 
episode by at least 1 minute of normalized ST-segment, was called 
ischemic. 
The number and duration of ischemic episodes and the total ischemic 
burden, defined as the area under the curve, or duration of ST-depression 
multiplied by mm of ST-depression, were registered for each treatment 
period. 
Exercise Tolerance Test 
The supine bicycle exercise test started at a workload of 30 W~ Every 
minute the workload increased by 10 W, until the patient stopped because 
of moderate angina, dyspnea, or fatigue. The ECG was monitored contin- 
uously, with a written conventional 12-lead ECG, blood pressure (BP), and 
heart rate (HR) registration at the end of each exercise l vel. Total exercise 
time, maximum workload, time to 0.1-mV ST-segment depression, maxi- 
mum ST-depression, and time to angina were registered for each patient. 
Statistical Ahal#sis 
Statistics were calculated using SPSS/PC ÷, version 4.01 (SPSS Inc., 
Chicago, IlLinois). As the observed parameters were not normally distrib- 
uted, Wilcoxon's matched-pairs signed-ranks test was used to compare 
treatment results with baseline values. 
RESULTS 
Patients 
Of the 29 patients (27 men and 2 women) who entered the random- 
ization phase, 6, all men, dropped out before the end of the study. One 
patient withdrew his consent, one had ventricular tachycardia, nd four 
complained of severe headache. Of the patients who dropped out, 4 had 
previous myocardial infarction. The remaining 23 patients (21 men and 2 
women) who completed the study were eligible for the efficacy analysis. 
Their mean age was 63 years (range, 41-76 y). Three patients had a 
previous myocardial infarction. Coronary angiography was performed 
in all patients: 19 patients had one-vessel disease, 2 had two-vessel dis- 
ease, and 2 had three-vessel disease. Of the patients who dropped out, 1 
had one-vessel disease, 3 had two-vessel disease, and 2 had three-vessel 
disease. 
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Exercise Test 
After each active treatment fewer patients reached 0.1-mV ST- 
depression (Table I). The mean exercise time until the occurrence of 0.1- 
mV ST-depression increased 6% (P < 0.05) with ISDN, 17% with biso- 
prolol (iv = 0.05), and 27% with the combination (P = 0.05). 
The max imum ST-depression during exercise was 0.02 mV lower with 
ISDN (P = 0.05), 0.05 mV lower with bisoprolol (P = 0.001), and 0.07 mV 
lower with the combination (P = 0.01) than with placebo. Compared with 
ISDN monotherapy, bisoprolol monotherapy lowered max imum ST- 
depression 0.035 mV more (P = 0.05) and the combination 0.052 mV more 
(P = 0.05). 
On active treatment significantly fewer patients had angina pectoris 
during the exercise test (Figure 1). 
Ambulatory Monitoring 
Although ISDN monotherapy did not significantly change the mean 
total number of ischemic episodes per 48 hours, the duration of the isch- 
emic episodes was 55% shorter (P = 0.05) and the total ischemic burden 
47% lower than with placebo (P = 0.05, Table II, Figure 2). 
Bisoprolol monotherapy lowered the mean number of ischemic epi- 
sodes per 48 hours by 74% (P --- 0.001), the duration ofischemia by 82% (P 
= 0.001), and the total ischemic burden by 83% (P = 0.001) compared with 
placebo. Compared with ISDN monotherapy, the mean number of episodes 
was 69% lower with bisoprolol monotherapy (P = 0.01), the duration of 
Table I. Comparison of exercise test data at the end of the placebo phase and at the end of 
each active treatment phase (n = 23). Values are expressed as mean ± SD except 
where noted. 
ISDN + 
Placebo ISDN 81soprolol Bisoprolol 
Total exercise time (min:s) 
Maximum workload (W) 
Maximum heart rate (beats/min) 
Maximum SBP(mm Hg) 
Patients with ST-depression (n) 
Time to 0.1-mV ST-depression 
(rain:s) 
Maximum ST depression (mV) 
Patients with angina (n) 
Time to angina pectoris (rain:s) 
9:01 ± 3:08 9:05 ± 3:04 9:11 ± 3:03 9:14 ± 2:49 
113 ± 33 114 ± 29 115 ± 30 116 ± 28 
129 ± 22 127 ± 21 105 ± 20* 98 ± 27* 
187 ± 26 180 ± 33 165 ± 26* 164 ± 30* 
23 20 18 16 
5:52 ± 3:03 5:14 ± 2:34t 6:53 ± 2:27t 7:28 ± 3:02t 
0.20 -+ 0.07 0.18 ± O.07t 0.15 ± 0.06"¢ 0.13 + 0.06$§ 
16 lOt lOt  5" 
7:39 ± 2:57 7:56 ± 354 8:32 23:08 8:51 -+ 3:16 
ISDN = isosorbide dinitrate; SBP = systolic blood pressure. 
* P < 0.01 compared with placebo. 
t P < 0.05 compared with placebo. 
¢ P < 0.05 compared with ISDN alone. 
§ P < 0.001 compared with placebo. 
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Figure 1. Number of patients with angina pectoris on exercise during each treatment phaCe, 
[SDN = isosorbide dinitrate. *P < 005, tP < 0.01 compared with placebo. 
ischemia 61% shorter (P = 0.05) ,  and the total ischemic burden 67% lower 
(P = 0.05). 
The combination of bisoprolol and ISDN significantly lowered all 
Holter parameters compared with placebo as well as compared with ISDN 
alone. The combination was not significantly better than bisoprolol alone 
for any of the parameters. The combination decreased the mean number of 
Table II. Comparison of mean Holter data per 48 hours during the placebo phase and at the 
end of each active treatment phase. Values are expressed as mean ± SD except 
where noted. 
ISDN + 
Placebo ISDN 81soprolol Blsoprolol 
No. o1 ischemic episodes 9.8 ± 4.5 B.Q +_ 8.8 2.5 _+ 3.5"t 2.2 ~_ 3.3"~" 
_ _ 45~L 17 + 33,§ 12 ± 21"§ Total duration of ischemia (rain) 97 + 101 44 -* 
Total isehemLc burden (mm × rain) 186 _+ 188 g8 + 1295 32 _ 59 § 24 ± 47*§ 
No. ot patients with angina 18 12 8 10 
No. ol anginal atlacks/4 weeks 4,1 ± 3.0 40 ± 40 2.8 ± 2.0 ~ 2.6 ± 2.8 ~ 
Percentage of silent ischemia (%) 92.0 98.21: 99.55 99.51: 
ISDN = isosorbide dinitrate. 
* P < 0.001 compared with ptacebo. 
1- P < 0.01 compared with ISDN alone. 
:~ P < 0.05 compared with placebo. 
§ P < 0,05 compared with ISDN alone, 
=1 p < 0.01 compared with placebo. 
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Figure 2. Mean total ischemic burden per 48 hours during different reatments. ISDN = 
isosorbide dinitrate. *P < 0.05, tP < 0.001. 
ischemic episodes per 48 hours by 78% compared with placebo (P = 0.001), 
while the mean total duration of ischemia became 88% shorter (P = 0.001) 
and the mean total ischemic burden 87% lower (P = 0.001). Compared 
with ISDN alone the combination decreased the mean number of ischemic 
episodes by 73% (P = 0.01), the mean duration of ischemia by 73% (P = 
0.05), and the total ischemic burden by 76% (P = 0.05). 
Patients experienced significantly fewer anginal attacks when they 
were receiving treatment with bisoprolol alone or with the combination 
(Table II). 
Circadian Variation of lschemia 
In the placebo phase, there was a clear circadian distribution of isch- 
emic episodes, duration of ischemia, and total ischemic burden measured 
by 48-hour Holter monitoring (Figure 3), with a high morning peak and a 
lower late-afternoon/early-evening peak. Bisoprolol monotherapy as well 
as the combination of bisoprolol and ISDN completely abolished the morn- 
ing and the evening peaks of ischemic events. ISDN treatment alone low- 
ered the evening peak, although less than bisoprolol, and it only slightly 
narrowed the morning peak. When the day was divided into 6ohour peri- 
ods, ISDN monotherapy significantly lowered the duration of ischemia 
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Figure 3. Circadian distribution of number of ischemic episodes per 24 hours during different 
treatments. ISDN = isosorbide dinitrate. 
(P = 0.01) and the total ischemic burden (P = 0.01) between 6 and 
12 PM. 
Tolerance 
Four patients dropped out of the study because of severe headache 
during ISDN treatment. One patient had ventricular tachycardia during 
the first active treatment phase with ISDN. Bisoprolol was generally well 
tolerated. 
DISCUSSION 
It is striking that the therapeutic differences between ISDN and bisoprolol 
were much more obvious during daily-activity Holter monitoring than 
during the exercise test. Whereas the Holter data showed large differences 
in the amount of silent ischemia in patients receiving ISDN or bisoprolol, 
both drugs were equally effective in reducing angina and ST-depression 
during ETT. Obviously, differences in anti-ischemic activity between 
drugs can be underestimated when only the ETT is used as a marker of 
efficacy. Also, in other studies similar discrepancies between ischemia 
during ETT or during daily activities have been shown. Studies with long- 
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acting nitrates showed that these drugs postpone the occurrence of anginal 
symptoms during exercise, I° but so far only relatively little or no influence 
on ambulatory ischemia, and none at all on its circadian variation, have 
been shown. 1°'15'16 
In our study, ISDN slightly altered the circadian variation of isch- 
emia--the evening peak in duration of ischemia and in the total ischemic 
burden was significantly lowered, although less pronounced than with 
bisoprolol. Beta-adrenergic blockers such as atenolol, metoprolol, or pro- 
pranolol effectively reduce both exercise-induced and ambulatory silent 
ischemia, abolishing the circadian variation, Is'17,1s and so does bisoprolol 
according to our study. Combination therapy with ISDN did not improve 
the effect of bisoprolol alone on the circadian variation of ischemia. 
An  explanation for the lack of effect of ISDN monotherapy especially 
on the morning peak in the circadian variation of ischemia could be that 
arousal of the sympathetic nervous system, with a consequent rise in blood 
pressure, heart rate, and myocardial oxygen demand, is a more important 
determinant of ischemia than coronary tonus, especially in the morning. In 
the evening, the sympathetic nervous system usually is less active, myo- 
cardial oxygen demand becomes a little lower, and drugs that improve 
myocardial oxygen supply, such as long-acting nitrates, may restore the 
oxygen supply-demand balance more easily. However, the fact that biso- 
prolol completely abolished the circadian variation of ischemia suggests 
that antagonism of sympathetic activity remains the most powerful tool to 
prevent or diminish ischemic events in the daily activities of our patients. 
In fact, bisoprolol improves the sympathico-vagal balance derived from the 
ratio of high- and low-frequency components of the heart rate variability. 19 
Combination therapy added little to this already strong effect. 
It was not possible to investigate to what extent nitrate tolerance 
accounted for the lower effectiveness of ISDN in our study, because the 
Holter monitoring and the ETT  took place only at the end of each 4-week 
treatment period and the effect thus could not be compared with the be- 
ginning of treatment. In our dosage schedule of ISDN 20 mg TID, the last 
dose was taken at 6 PM in order to avoid nitrate tolerance, as has been 
shown in other studies. 12-14 The effectiveness of ISDN against anginal 
complaints and ST-depression during the ETT, and its relative effective- 
ness against ambulatory ischemia in the afternoon and evening hours, also 
argue against the occurrence of nitrate tolerance in our study. 
The fact that exercise time was not significantly prolonged by either 
medication may be due to the selection of patients. Although all patients 
had anamnestic exercise-induced angina, they were selected on the basis of 
ST-depression during exercise and did not necessarily stop because of an- 
gina. In some patients exercise duration was already limited by fatigue or 
dyspnea on placebo. Active medication may also have caused early fatigue 
during exercise, an effect that is found more often in studies of beta- 
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adrenergic blockers. Whether this is true also for long-acting nitrates is 
not clear. 
In studies of ischemic episodes recorded by Holter monitoring, the 
therapeutic effects may be overshadowed not only by day-to-day variabil- 
ity of the occurrence of ischemia, but also by a regression to the mean 
effect, if the presence of ischemic episodes is a selection criterion for en- 
trance to the study. 2° In comparing the effect of two drugs in the same 
patients, regression to the mean may play a role in measuring the absolute 
effect, but not the relative effect of one drug compared with the other. To 
diminish the effect of day-to-day variability and thus diminish the regres- 
sion to the mean, we used a relatively long, 48-hour, Holter measurement. 
According to a study by Deanfield and Spiegelhalter, 21in a sample of 20 
patients using 48-hour Holter monitoring, at least a 30% reduction in the 
number of ischemic episodes is required to have 80% power of reaching 
statistical significance. According to another study by Nademanee, 22in a 
sample of 23 patients, with only 24-hour Holter monitoring, the reduction 
in duration of myocardial ischemia should be at least 47% to have 80% 
power of reaching statistical significance. In our study, with 23 patients 
and a 48-hour duration of the Holter monitoring, we may expect that 
<30% of the reduction in number of ischemic episodes and <47% of the 
reduction in duration of ischemia during the active treatments i due to 
regression to the mean. The reduction in number of ischemic episodes we 
found with ISDN was quite small, only 18%, which was not statistically 
significant, and argues against a substantial regression-to-the-mean ef- 
fect. In contrast, the reduction in duration of ischemia with ISDN was 
much larger, 55%, which exceeded the estimated regression to the mean 
and was statistically significant. With bisoprolol or combination treat- 
ment, the reduction in all ischemic parameters in our study was far larger 
than the possible regression to the mean. But even if the effect of regres- 
sion to the mean accounts for some of the decrease in ischemia during the 
active treatments, this decrease may be expected to be the same for all 
treatment phases. Thus the differences between bisoprolol or bisoprolol/ 
ISDN treatment and ISDN treatment alone are certainly not influenced by 
this effect. 
The therapeutic relevance of our findings is not yet clear. Whether 
effective treatment of all silent ischemia during daily activity leads to a 
better prognosis has not been prospectively proven. Ongoing long-term 
studies may answer this question. 23 The concordant positive influence of 
beta-adrenergic blockers on total ischemic burden, myocardial infarction, 
and sudden death suggests that there may be a positive influence of treat- 
ment. 24-26 The Atenolol Silent Ischemia Study suggests a positive influ- 
ence of atenolol treatment on the occurrence of adverse events during 
1-year follow-up of patients with silent ischemia, although the effect on 
mortality was not significantY In contrast o beta- and adrenergic blockers 
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and calcium antagonists, no studies on the long-term cardioprotective f- 
fects of long-acting nitrates in silent ischemia have been performed. Fu- 
ture studies will have to determine whether the relative lack of influence 
of nitrates on ambulatory ischemia and its circadian variation is accom- 
panied by a lack of long-term cardioprotection. 
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